

Binge-eating disorder - Pipeline Insight, 2021

<https://marketpublishers.com/r/B598FC4CB02EN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: B598FC4CB02EN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Binge-eating disorder - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Binge-eating disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Binge-eating disorder Understanding

Binge-eating disorder: Overview

Binge eating disorder (BED) is a mental illness characterised by regular episodes of binge eating. Binge eating involves eating an excessive amount of food, which may take place in a rapid space of time, or may be more of an extended grazing. These episodes can feel chaotic, uncontrollable and highly distressing. During a binge eating episode, a person may not be hungry, but may continue to eat past the point of feeling comfortably full. It is common for people to binge eat alone or in secret, and experience intense feelings of guilt, shame, disgust and low mood after a binge. A binge is different from overeating and is far more pervasive. It is the intense drive to overeat which is experienced again and again over time, accompanied by feelings of shame, guilt and feeling out of control.

'Binge-eating disorder - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Binge-eating disorder pipeline landscape is provided which includes the disease overview and Binge-eating disorder treatment guidelines. The assessment part of the report embraces, in depth Binge-eating disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Binge-eating disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Binge-eating disorder R&D. The therapies under development are focused on novel approaches to treat/improve Binge-eating disorder.

Binge-eating disorder Emerging Drugs Chapters

This segment of the Binge-eating disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Binge-eating disorder Emerging Drugs

SEP-225289: Sumitomo Dainippon Pharma

SEP-225289 is a dopamine and norepinephrine reuptake inhibitor (DNRI). SEP-225289 has an extended half-life (47-77 hours) that supports the potential for plasma concentrations yielding a continuous therapeutic effect over the 24-hour dosing interval.

ACT-539313: Idorsia Pharmaceuticals

ACT-539313 is an Orexin receptor type 1 antagonist being developed by Idorsia Pharmaceuticals. Currently, it is in Phase II stage of clinical trial evaluation to treat Binge-eating disorder.

Further product details are provided in the report.....

Binge-eating disorder: Therapeutic Assessment

This segment of the report provides insights about the different Binge-eating disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Binge-eating disorder

There are approx. 4+ key companies which are developing the therapies for Binge-eating disorder. The companies which have their Binge-eating disorder drug candidates in the most advanced stage, i.e. phase II include, Idorsia Pharmaceuticals.

Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Binge-eating disorder pipeline report provides the therapeutic assessment of the

pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Binge-eating disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Binge-eating disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Binge-eating disorder drugs.

Binge-eating disorder Report Insights

Binge-eating disorder Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Binge-eating disorder Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Binge-eating disorder drugs?

How many Binge-eating disorder drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Binge-eating disorder?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Binge-eating disorder therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Binge-eating disorder and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Sumitomo Dainippon Pharma

Idorsia Pharmaceuticals

Takeda

Bright Minds Biosciences

Praxis Bioresearch

Key Products

SEP-225289

ACT-539313

Vortioxetine

BMB-101

PRX-P4-003

Contents

Introduction

Executive Summary

Binge-eating disorder: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Binge-eating disorder – DelveInsight's Analytical Perspective

Late Stage Products (Preregistration)

Comparative Analysis

SEP-225289: Sumitomo Dainippon Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

ACT-539313: Idorsia Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
BMB-101: Bright Minds Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report

Inactive Products
Comparative Analysis
Binge-eating disorder Key Companies
Binge-eating disorder Key Products
Binge-eating disorder- Unmet Needs
Binge-eating disorder- Market Drivers and Barriers
Binge-eating disorder- Future Perspectives and Conclusion
Binge-eating disorder Analyst Views
Binge-eating disorder Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Binge-eating disorder

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Binge-eating disorder
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Binge-eating disorder - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/B598FC4CB02EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B598FC4CB02EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970